EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices

using neuroblocking technology to treat obesity, metabolic diseases

and other gastrointestinal disorders, today announced that Gregory S.

Lea, Senior Vice President and Chief Financial Officer, is scheduled

to present at the 24th Annual ROTH Capital Growth Conference on

Wednesday, March 14th at 2:00 pm PT, at The Ritz Carlton in Laguna

Niguel, California. Mr. Lea will provide an overview of the Company

and an update on its VBLOC@ vagal blocking therapy development


Additionally, the Company will be hosting one-on-one meetings

throughout the day. Institutional investors that would like to request

a meeting should contact ROTH Capital directly.

The presentation will be webcast live and may be accessed by visiting

EnteroMedics' website at A replay of the

webcast will also be available immediately after the conclusion of the

presentation for a period of thirty days. Investors can access the

webcast under "Press Room" in the "Investors" section of EnteroMedics


About EnteroMedics Inc.

EnteroMedics is a development stage medical device company focused on

the design and development of devices that use neuroblocking

technology to treat obesity, metabolic diseases, and other

gastrointestinal disorders. EnteroMedics' proprietary neuroblocking

technology, VBLOC@ vagal blocking therapy, is designed to

intermittently block the vagus nerves using high-frequency,

low-energy, electrical impulses. These electrical impulses are

delivered by a neuroregulator, EnteroMedics' Maestro@ System, which is

powered by an integrated rechargeable battery. For more information,


Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements about

EnteroMedics Inc. Our actual results could differ materially from

those discussed due to known and unknown risks, uncertainties and

other factors including our limited history of operations; our losses

since inception and for the foreseeable future; our lack of commercial

regulatory approval for our Maestro@ System for the treatment of

obesity in the United States or in any foreign market other than

Australia and the European Community; our preliminary findings from

our EMPOWER pivotal trial; our ability to comply with the Nasdaq

continued listing requirements; our ability to commercialize our

Maestro System; our dependence on third parties to initiate and

perform our clinical trials; the need to obtain regulatory approval

for any modifications to our Maestro System; physician adoption of our

Maestro System and VBLOC@ vagal blocking therapy; our ability to

obtain third party coding, coverage or payment levels; ongoing

regulatory compliance; our dependence on third party manufacturers and

suppliers; the successful development of our sales and marketing

capabilities; our ability to raise additional capital when needed;

international commercialization and operation; our ability to attract

and retain management and other personnel and to manage our growth

effectively; potential product liability claims; potential healthcare

fraud and abuse claims; healthcare legislative reform; and our ability

to obtain and maintain intellectual property protection for our

technology and products. These and additional risks and uncertainties

are described more fully in the Company's filings with the Securities

and Exchange Commission, particularly those factors identified as

"risk factors" in the current report on Form 8-K filed September 28,

2011. We are providing this information as of the date of this press

release and do not undertake any obligation to update any

forward-looking statements contained in this document as a result of

new information, future events or otherwise.

Caution - Investigational device. Limited by Federal (United States)

law to investigational use.

The implantation procedure and usage of the Maestro@ System carry some

risks, such as the risks generally associated with laparoscopic

procedures and those related to treatment as described in the ReCharge

clinical trial informed consent.